PT  - JOURNAL ARTICLE
AU  - Angiolillo, Dominick
TI  - BRIDGE Study Demonstrates Feasibility and Safety of Cangrelor
DP  - 2011  01
TA  - MD Conference Express
PG  - 10--11
VI  - 11
IP  - 14
4099  - http://mdc.sagepub.com/content/11/14/10.short
4100  - http://mdc.sagepub.com/content/11/14/10.full
AB  - Cangrelor is a rapid-acting, reversible, intravenous ADP-P2Y12 receptor antagonist with a plasma half-life of 3 to 6 minutes. The Maintenance of Platelet Inhibition With Cangrelor After Discontinuation of Thienopyridines in Patients Undergoing Surgery [BRIDGE; NCT00767507] study results evaluated the use of cangrelor for bridging thienopyridine-treated patients to coronary artery bypass graft.